Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis.
BACKGROUND
The impact of moxifloxacin (MOX) was analyzed in the treatment of severe chronic periodontitis.


METHODS
In a randomized, prospective, clinical multicenter trial, 92 subjects with severe chronic periodontitis were treated with scaling and root planing (SRP) alone (control group; n = 21), SRP plus adjunctive doxycycline (DOX group; n = 36), or SRP plus adjunctive MOX (MOX group; n = 35). Probing depth (PD), clinical attachment level (CAL), and bleeding on probing (BOP) were recorded at baseline and at 3, 6, and 12 months after non-surgical periodontal treatment. The load of periodontopathogens, the level of interleukin-8, and the activities of granulocyte elastase and myeloperoxidase were also measured.


RESULTS
All three procedures led to significant reductions in PD, CAL, and BOP. PD reduction was significantly greater (P <0.05) in the MOX group (2.46 +/- 1.17 mm at 6 months and 2.84 +/- 1.53 mm at 12 months) compared to the DOX group (1.85 +/- 1.24 mm and 2.19 +/- 1.13 mm at 6 and 12 months, respectively) and the controls (1.77 +/- 0.57 mm and 1.86 +/- 0.56 mm at 6 and 12 months, respectively). Only in the MOX group was the load of all investigated bacteria and all inflammatory parameters reduced at each appointment compared to baseline.


CONCLUSIONS
The adjunctive application of antibiotics improved the treatment outcome in subjects with severe chronic periodontitis. MOX seemed to be more effective than DOX and might be an alternative drug in the treatment of periodontal diseases.
Guentsch
Arndt
A
Department of Conservative Dentistry, University Hospital of Jena, Jena, Germany. arndt.guentsch@med.uni-jena.de
Jentsch
Holger
H
Pfister
Wolfgang
W
Hoffmann
Thomas
T
Eick
Sigrun
S
D000328:Adult; D016976:Aggregatibacter actinomycetemcomitans / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D001439:Bacteroides / Q000302:isolation & purification; D055113:Chronic Periodontitis / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D015169:Colony Count, Microbial; D003131:Combined Modality Therapy; D012534:Dental Scaling; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000188:drug therapy / Q000628:therapy; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis; D019272:Leukocyte Elastase / Q000032:analysis; D008297:Male; D000077266:Moxifloxacin; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000628:therapy; D010514:Periodontal Pocket / Q000188:drug therapy / Q000628:therapy; D009195:Peroxidase / Q000032:analysis; D016966:Porphyromonas gingivalis / Q000302:isolation & purification; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*; D016745:Root Planing; D016896:Treatment Outcome; D048373:Treponema denticola / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D016209:Interleukin-8; D011804:Quinolines; D009195:Peroxidase; D019272:Leukocyte Elastase; D004318:Doxycycline; D000077266:Moxifloxacin